Company Overview

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to enhance the delivery and effectiveness of cancer vaccines and immune-modulating therapeutics. The company operates within the biotechnology and oncology sectors, with a primary emphasis on lymph node-targeted immunotherapies intended to stimulate antigen-specific T-cell responses against solid tumors. Its platform technologies are centered on amphiphile (“AMP”) modification technology, which is designed to improve trafficking of therapeutic compounds to lymph nodes after administration.

The company’s principal product candidates have included ELI-002, an investigational therapeutic cancer vaccine targeting KRAS-driven cancers, particularly pancreatic and colorectal cancers with KRAS mutations. Elicio’s strategy has focused on addressing minimal residual disease and relapse prevention in high-risk oncology settings. The company evolved from earlier platform-development efforts into a more oncology-focused clinical-stage enterprise and became publicly traded through a merger transaction involving Angion Biomedica Corp., after which the combined company adopted the Elicio Therapeutics name and Nasdaq ticker symbol “ELTX.”

Business Operations

Elicio Therapeutics primarily operates as a single-segment clinical-stage biotechnology company, generating activities centered on research and development rather than commercial product sales. Revenue has historically been derived mainly from collaboration arrangements, licensing activities, financing transactions, and capital market operations, while operating expenses are concentrated in clinical development, manufacturing, and scientific research. The company’s core asset base includes its proprietary AMP platform technology, intellectual property related to lymph node targeting, and oncology-focused immunotherapy candidates.

Operational activities are concentrated in the United States, including clinical development, regulatory engagement, and corporate administration. Elicio has relied on contract research organizations, clinical investigators, and third-party manufacturing partners to support development programs. Its lead oncology programs have included collaborations with academic cancer centers and clinical trial networks evaluating therapeutic vaccine approaches in KRAS-mutated cancers. Public disclosures indicate that the company maintains strategic relationships with external manufacturing and development partners, though some operational partnership details are limited in publicly available filings.

Strategic Position & Investments

Elicio Therapeutics’ strategic direction has centered on advancing lymph node-targeted immunotherapies intended to improve anti-tumor immune responses in difficult-to-treat cancers. The company has prioritized clinical advancement of ELI-002, including studies in patients with KRAS-mutated pancreatic ductal adenocarcinoma and colorectal cancer. Management has emphasized the potential for AMP-enabled therapies to generate stronger and more durable T-cell activation compared with conventional peptide vaccine approaches.

The company’s investments have focused primarily on clinical development, platform expansion, and manufacturing capabilities supporting personalized or mutation-specific immunotherapies. Following the reverse merger involving Angion Biomedica Corp., Elicio consolidated operations around oncology and immunotherapy development. Public filings and investor materials indicate continued interest in expanding applications of its AMP platform across additional tumor-associated antigens and potentially broader immuno-oncology indications. Data regarding material portfolio company holdings or extensive subsidiary structures is inconclusive based on available public sources.

Geographic Footprint

Elicio Therapeutics is headquartered in Cambridge, Massachusetts, within the biotechnology corridor of the northeastern United States. Its operational footprint is primarily concentrated in the United States, where it conducts corporate operations, clinical management activities, and regulatory interactions with the U.S. Food and Drug Administration. Clinical trial participation has included multiple U.S.-based cancer treatment centers and research institutions.

While the company does not maintain the extensive international commercial infrastructure typical of large pharmaceutical companies, its clinical development activities and investor outreach have had broader international relevance within the oncology and biotechnology sectors. Public disclosures indicate limited direct global operational infrastructure outside the United States, though clinical supply chains and development partnerships may involve international service providers.

Leadership & Governance

Elicio Therapeutics has been led by executives with backgrounds in biotechnology, oncology drug development, immunology, and capital markets. Leadership has consistently emphasized precision immunotherapy, translational oncology, and the development of lymph node-targeted therapeutic platforms intended to improve patient outcomes in mutation-driven cancers.

Key executives identified in recent public filings and company disclosures include:

• Robert Connelly – President and Chief Executive Officer
• Andrew Allen, M.D., Ph.D. – Chief Scientific Officer
• Thomas Schuetz, M.D., Ph.D. – Chief Medical Officer
• Brian Miller – Chief Financial Officer

The company’s governance framework includes a board of directors with experience spanning biotechnology development, clinical medicine, pharmaceutical commercialization, and healthcare investment. Strategic messaging from leadership has focused on advancing clinically differentiated immunotherapies while maintaining disciplined capital allocation and milestone-driven development priorities.